FORMULATION ARTICLES
-
Location Matters: How The Nuclear Geography Of circRNAs Could Shape The Future Of RNA Therapeutics
CircRNA location may be as important as its sequence. Discover how nuclear organization could influence the next generation of RNA therapeutics.
-
Building The RNA Knowledge Graph: How Better Annotation Is Accelerating Therapeutic Discovery
As RNA therapeutics grow more complex, better biological annotation is becoming the foundation for AI-driven discovery, target selection, and smarter drug development.
-
Building A Self-Driving Lab For LNP Development
With commercially available components, MIT researchers built a platform that accelerates LNP process development, optimization, and autonomous manufacturing research.
-
Beyond Vaccines: Can RNA Sense Gases?
Could RNA sense its environment? A new hypothesis explores how RNA may detect temperature and gases, inspiring smarter, adaptive RNA therapeutics.
-
Decoding RNA's Circular Decisions: How HNRNPD Shapes circRNA Biogenesis And RNA Fate
How do cells decide between circular and linear RNA? New insights into HNRNPD reveal mechanisms that could improve the design of future circRNA therapeutics.
-
Beyond Gene Silencing: Harnessing Regulatory RNAs To Increase Gene Expression In Haploinsufficient Disease
Can RNA therapeutics increase — not silence — gene expression? Regulatory RNA-targeting ASOs may redefine treatment for haploinsufficient diseases.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Accelerate essential process development activities with instrumentation solution allowing for highly reproducible and scalable production of RNA-LNPs.
-
Single-use technology is vital for ensuring the quality and expedited market entry of genomic medicines. Learn how LNP technology is paving the way for a new era of personalized, precise medicine.
-
Here, we highlight three important process considerations across the RNA-LNP manufacturing workflow which includes limit size behavior, in-line dilution and downstream tangential flow filtration (TFF).
-
Experts note CGT programs often struggle due to limited operational readiness; early standardization supports scalable, reproducible, regulatory‑ready development and helps prevent late‑stage bottlenecks.
-
Risk analysis and lane qualification show supply chains perform consistently, meeting regulatory expectations by demonstrating control, reducing variability, and ensuring reliable delivery.
-
Gene delivery platforms must support a diversity of genetic engineering strategies for genomic medicine development. Learn how lipid nanoparticles can accelerate development from discovery to scale-up.
-
Learn how buffer choice, gradient strategy, and pretreatment steps influence recovery, purity, and resolution when purifying a native RNA oligo, with analytical confirmation and practical guidance.